Generally, Zepbound treatment is roughly RM1,800RM3,000 per month, while Mounjaro is roughly RM1,800RM6,000 per month
Guney-Coskun M, Basaranoglu M
In findings presented at the European Association for the Study of Diabetes and simultaneously published in the Journal of Endocrinological Investigation , researchers obtained reports of gastrointestinal adverse events, pancreatitis, cholecystitis, cholelithiasis, diabetes retinopathy and thyroid neoplasm for people using tirzepatide (Mounjaro/Zepbound, Eli Lilly), a GLP-1/GIP receptor agonist, from the FDA Adverse Events Reporting System database
J Diabetes Complications
The company operates from a verifiable physical address in Delray Beach, Florida, under the legal entity Melex Technologies